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Abstract
This systematic review and meta-analysis investigated ω-3 fatty-acid enriched parenteral nutrition (PN) vs standard (non-ω-3 fatty-
acid enriched) PN in adult hospitalized patients (PROSPERO 2018 CRD42018110179). We included 49 randomized controlled
trials (RCTs) with intervention and control groups given ω-3 fatty acids and standard lipid emulsions, respectively, as part of PN
covering 70% energy provision. The relative risk (RR) of infection (primary outcome; 24 RCTs) was 40% lower with ω-3 fatty-
acid enriched PN than standard PN (RR 0.60, 95% confidence interval [CI] 0.49-0.72; P < 0.00001). Patients given ω-3 fatty-acid
enriched PN had reduced mean length of intensive care unit (ICU) stay (10 RCTs; 1.95 days, 95% CI 0.42-3.49; P = 0.01) and
reduced length of hospital stay (26 RCTs; 2.14 days, 95% CI 1.36-2.93; P < 0.00001). Risk of sepsis (9 RCTs) was reduced by 56%
in those given ω-3 fatty-acid enriched PN (RR 0.44, 95% CI 0.28-0.70; P= 0.0004). Mortality rate (co-primary outcome; 20 RCTs)
showed a nonsignificant 16% reduction (RR 0.84, 95% CI 0.65-1.07; P = 0.15) for the ω-3 fatty-acid enriched group. In summary,
ω-3 fatty-acid enriched PN is beneficial, reducing risk of infection and sepsis by 40% and 56%, respectively, and length of both ICU
and hospital stay by about 2 days. Provision of ω-3-enriched lipid emulsions should be preferred over standard lipid emulsions in
patients with an indication for PN. (JPEN J Parenter Enteral Nutr. 2020;44:44–57)
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Introduction
Lipid emulsions are a key component of parenteral nutri-
tion (PN) and are used as an energy-dense source of calories,
reducing the glycemic load, supplying essential fatty acids,
and lowering osmolarity.1,2 The first generation of lipid
emulsions was based on soybean oil or soybean/safflower
oil and characterized by high concentrations of long-chain
triglycerides providing high levels of ω-6 polyunsaturated
fatty acids (PUFAs).1,3 However, concerns arose that soy-
bean oil lipid emulsions could promote inflammation and
suppress immune function, thought to be related partly to
an excess of ω-6 PUFAs and a low concentration of ω-3
PUFAs.3-5
The idea that ω-6 PUFAs might be “proinflammatory
and immunosuppressive” led to the development of alter-
native lipid emulsions, including the partial replacement
of soybean oil with medium-chain triglycerides, olive oil,
and by the inclusion of fish oil.3-5 Fish oil has been
shown to have anti-inflammatory and immunomodulatory
effects, most likely because of fish oil’s ω-3 PUFA content,
consisting of docosahexaenoic acid (DHA) and eicosapen-
taenoic acid (EPA) as they influence diverse inflammatory
processes – from signal transduction to protein expression.6
EPA and DHA are now known to be direct precursors
of potent specialized proresolution mediators (ie, resolvins,
protectins, and maresins) that improve outcomes in many
animal disease models.7 Fish oil may oppose the actions
of ω-6 PUFAs, improve hepatic metabolism and liver func-
tion, and exert anticoagulatory and antiarrhythmic effects.3
Thus, many trials have compared PN with or without
fish oil to explore potential benefits for certain clinical
conditions, in particular those characterized by an inflam-
matory over-response (eg, sepsis, pancreatitis, acute respi-
ratory distress syndrome, and following major abdominal
surgery).
The use of systematic reviews and meta-analyses is
crucial to the formulation of guidelines, as they are the
most powerful methods to inform healthcare decisions
and form the highest level of the evidence-based medicine
hierarchy,8 summarizing evidence to allow judgement of
risks and benefits.9 In our previous meta-analysis we found
significant clinical benefits for ω-3 fatty-acid enriched PN
in hospitalized patients.10 The rationale for an update is
that many new clinical trials have been published, and
though other recent meta-analyses have been performed,
these do not have as broad a scope as our 2012 publication.10
Furthermore, the update will adapt (1) the inclusion criteria
to more closely match clinical practice and (2) the method-
ology to reflect the latest meta-analyses requirements. Thus,
the objective for this new systematic review and meta-
analysis was to investigate potential benefits of ω-3 fatty-
acid enriched PN vs standard PN in adult hospitalized
patients.
Methods
Registration and Overview
The protocol was published prospectively (PROSPERO
2018CRD42018110179).11 The systematic review andmeta-
analysis covered ω-3 fatty-acid enriched PN vs standard
(non-ω-3 fatty-acid enriched) PN in adult hospitalized pa-
tients regarding clinical efficacy and laboratory parameter
outcomes. The methods can be summarized as follows:
(a) defining the eligibility criteria, (b) identification of
databases and search strategy, (c) performing a structured
literature search to identify publications followed by study
selection based on title, abstract, and full text, progressively,
and (d) data extraction and synthesis of the results.
Eligibility Criteria
Eligibility criteria for included studies are shown according
to participants, interventions, comparisons, outcomes, and
study designs (PICOS).12,13
Participants. Publications included human studies of adult
hospitalized patients (later assigned as being within an
intensive care unit [ICU] or non-ICU setting, as defined by
the authors using the criteria that ICU studies should have
a mean of at least 48 hours in an ICU) who were eligible
to receive PN covering at least 70% of their total energy
provision. This excluded nontarget populations (ie, pediatric
or neonatal patients), or enteral nutrition studies.
Interventions and comparisons. Interventions and compara-
tors included were ω-3 fatty-acid enriched PN and stan-
dard (non-ω-3 fatty-acid enriched) PN, respectively. This
excluded “off-label” interventions (specifically in which fish
oil was used as the sole source of parenteral lipids), and
studies in which enteral nutrition accounted for >30% of
the daily caloric provision.
Outcomes. Clinical outcomes were infection rate (primary
outcome), mortality rate (co-primary outcome), length of
hospital stay, length of ICU stay, sepsis rate, hospital
readmissions, ICU-free days until day 30 or day 60, and
ventilation-free days until day 30 (note: sepsis included
events defined by publication authors as septic or systemic
inflammatory response syndrome; see Table S1). Other
outcomes were transfused blood units and oxygenation
index, fatty-acid composition of plasma phospholipids and
lipid profile (α-tocopherol, EPA, DHA, arachidonic acid,
plasma triglycerides), markers of inflammation and an-
tioxidant status (interleukin-6, leukotriene [LT] B5, LTB4,
LTB5:LTB4 ratio, C-reactive protein, tumor necrosis factor
[TNF]-α), and routine laboratory parameters (lactate; urea;
serum creatinine; creatinine clearance; platelets; prothrom-
bin time; partial thromboplastin time [PTT]; international
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normalized ratio; bleeding time; liver enzymes aspartate
[AST], alanine aminotransferase [ALT], and γ -glutamyl
transferase [GGT]; and total bilirubin).
Study design. Randomized controlled trials (RCTs) pub-
lished in English in peer-review journals containing at least
1 predefined outcome were included.
Information Sources and Search Methods
Keywords for the search were “parenteral nutrition,” “fish
oil,” “omega-3,” “lipids,” “emulsion,” and “randomized
controlled trial.” The search strategy was formulated a
priori in a structured manner using the PICOS criteria.11-13
No restrictions or filters were used, and exclusions were
based on the selection process defined in the eligibility
criteria. The time interval of inclusion was from any date
to present (September 28, 2018). MEDLINE (PubMed
interface), EMBASE (Elsevier interface), and the Cochrane
Central Register of Controlled Trials (Wiley interface)
were searched. The search string was modified according
to each database’s requirements.11 Results were combined
to eliminate duplicates using an Excel-based algorithm,
constituting the core systematic review database. Manual
searches were performed of reference lists of included
studies, plus reviews andmeta-analyses on the subject. Extra
RCTs identified were integrated into the core database.
Study Selection, Data Collection, and Data
Items
Two review authors independently screened titles and ab-
stracts of all publications in the core database against the
eligibility criteria. The full text of eligible papers was then
checked against the inclusion criteria and to ensure no ex-
clusion criteria were present. Conflicting opinions were dis-
cussed with a third review author, and original publication
authors were consulted for clarification if necessary. Two
authors independently extracted data from each trial using
a predefined standardized collection grid. Disagreements
were resolved in consultation with the principal investigator.
If outcomes were only shown in a graphical format, then
numerical values were extrapolated using Engauge digitizer
software version 10.11.14 Outcomes were reported as SI
units or those prevalent in clinical practice. Standard error
of the mean (SEM) values were transformed into standard
deviations (SD) using standard formulas. Data reported
as median and interquartile range were converted into
estimated mean and SD using the formulas suggested in
Wan et al.15 When dispersion data (SD/SEM) were missing,
the original authors of the study were contacted. If these
data could not be obtained, an imputation based on the
coefficient of variation (SD/mean) of all available data was
performed.
Risk of Bias in Individual Studies
Included trials were assessed by 2 reviewers working inde-
pendently using the Cochrane Collaboration tool for assess-
ing the risk of bias.12 If there was insufficient detail reported
in the study, the risk of bias was judged as “unclear,” and
the original study investigators were contacted for more
information.
Summary Measures
For continuous outcomes, the summary measure was the
weighted mean difference (with 95% confidence interval
[CI]), although standardized mean difference was used in
the case of different measurement scales. For dichotomous
outcomes, the summarymeasure was relative risk (RR) with
95%CI. The proportional odds ratio was used as a summary
measure for categorical outcomes on an ordinal scale.
Synthesis of Results (Meta-Analysis) and Trial
Sequential Analysis
Data from included studies was statistically combined
through meta-analysis using ReviewManager (RevMan5.3;
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). All methods applied are thoroughly
detailed in the Cochrane Handbook.12 As per Cochrane
Handbook recommendations,12 analyses were performed
first via fixed effect models, based on which heterogeneity
was analyzed. Trial sequential analyses were performed
for all primary and secondary outcomes with a signifi-
cant pooled effect using TSA 0.9.5.10 beta (Copenhagen
Trial Unit, Centre for Clinical Intervention Research,
Copenhagen, Denmark, 2011) as detailed in the published
protocol.11 This explored whether the pooled analyses were
adequately powered to evaluate treatment effect on out-
comes.
Subgroup Analyses and Meta-Regression
For highly heterogeneous outcomes (I2 > 50%), data
were included in random effects models. Any source of
heterogeneity, or outcomes with 10 studies, underwent
subgroup analyses and meta-regression, stratifying data by
patient characteristics, intervention, study characteristics,
and clinical setting. Mantel–Haenszel study weighting was
performed for dichotomous outcomes, and inverse variance
was used for continuous data. The DerSimonian and Laird
inverse-variance approach was used for random effects
meta-analysis, adjusting study weights by heterogeneity
among intervention effects. The between-study variation
was estimated by comparing each study’s intervention effect
with the pooled estimate of the corresponding fixed effects
analysis. Note: a 0-cell correction was applied for meta-
analyses of dichotomous and count of events data in studies
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Identified through the 3
database searches (n = 4495)
Identified through manual reference
check of included papers (n = 1)
Publications screened by title
and abstract (n = 2992)
After screening by title and
abstract (n = 78)
Included in meta-analyses
(n = 49)
Included in qualitative synthesis
(n = 49)
Full-text artciles assessed for
eligibility (n = 49)
Studies excluded (n = 2914) because of: 
intervention (n = 883), population 
(n = 24), not randomized controlled 
trial (n = 791), language (n = 139), not 
human (n = 338), not adult (n = 303), 
enteral feeding study (n = 132), 
retracted (n = 1), no longer published 
(n = 1), not available (n = 1), Cochrane 
reviews (n = 301)
Studies excluded (n = 29) because of: 
off-label use (fish oil as the only lipid 
source) (n = 7), wrong patient 
population (n = 6), not English (n = 4), 
no outcome under consideration 
(n = 3), enteral feeding studies (n = 2), 
no intervention of interest (n = 2), not
 randomized controlled trial (n = 1), not 
human study (n = 1), and publication
issues (n = 3; 2 of which were 
subgroups of larger published 
studies already included, and 1 
was a duplicate PubMed record).
Publications after duplicates
removed (n = 2992) Duplicates excluded (n = 1503)
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Figure 1. Study selection and screening.
in which there were no events in 1 or both groups, requiring
STATA statistical software (STATA 14.2, StataCorp LLC,
College Station, TX, USA).
Risk of Bias Across Studies (Meta Bias) and
Confidence in Cumulative Estimate
Risk of bias that could affect the cumulative evidence (eg,
publication bias, selective reporting within studies) was
assessed by checking whether a protocol for each RCT was
published before the RCT was conducted and by evaluat-
ing whether selective reporting of outcomes was present.
Reporting bias was further explored by funnel plots if 10
studies were available. Confidence in cumulative estimates
for all statistically significant outcomes was judged using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) working group methodology
using GRADEpro v.3.6.1 (GradePro.org).16
Results
Study Selection and Characteristics
A total of 49 studies with 3641 patients were included in the
review and meta-analysis (Figure 1 and Table 1).10,17-65
Clinical Outcomes
For the primary outcome, infection rate, 24 studies (2154
patients) were included that reported any nosocomial
infections: 7 studies for ICU patients and 17 for non-
ICU patients. Compared with standard lipid emulsions,
ω-3 fatty-acid enriched PN resulted in a significant 40%
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(A) Random sequence generation (selection bias)
Risk of bias legend
(G) Other bias
(F) Selective reporting (reporting bias)
(E) Incomplete outcome data (attrition bias)
(D) Blinding of outcome assessment (detection bias)
(C) Blinding of participants and personnel (performance bias)
(B) Allocation concealment (selection bias)
Low risk
High risk
Unclear
Badia-Tahull, 2010 3 13 11 14 4.9% 0.29 [0.10, 0.82]
Chen, 2017 4 40 8 40 3.7% 0.50 [0.16, 1.53]
Friesecke, 2008 11 83 12 82 5.6% 0.91 [0.42, 1.93)
Zhu, 2012 3 33 6 33 2.8% 0.50 [0.14, 1.83]
Zhu, 2013 14 38 22 38 10.1% 0.64 [0.39, 1.05]
Total (95% CI)  1083  1071 100.0% 0.60 [0.49, 0.72]
Total events 131  215
Heterogeneity: χ2 = 13.63, df = 23 (P = 0.94); I2 = 0%
Test for overall effect: Z = 5.26 (P < 0.00001)
Zhu, 2012 4 29 8 28 3.7% 0.48 [0.16, 1.42]
Grau-Carcoma, 2015 17 81 29 78 13.6% 0.56 [0.34, 0.94]
Han, 2012 5 18 5 12 2.8% 0.67 [0.24, 1.81]
Jiang, 2010 4 100 12 103 5.4% 0.34 [0.11, 1.03]
Klek, 2008 12 51 13 49 6.1% 0.89 [0.45, 1.75]
Klek, 2011 9 42 10 41 4.7% 0.88 [0.40, 1.94]
Klek, 2005 5 30 8 30 3.7% 0.63 [0.23, 1.69]
Liang, 2008 1 20 1 21 0.4% 1.05 [0.07, 15.68]
Ma, 2015 3 51 1 48 0.5% 2.82 [0.30, 26.22]
Makay, 2011 1 14 2 12 1.0% 0.43 [0.04, 4.16]
Senkal, 2007 4 19 7 21 3.1% 0.63 [0.22, 1.82]
Wachtler, 1997 0 19 2 21 1.1% 0.22 [0.01, 4.31]
Wang, 2012 3 32 4 31 1.9% 0.73 [0.18, 2.99]
Wang, 2009 6 28 9 28 4.1% 0.67 [0.27, 1.62]
Wei, 2014 1 26 6 26 2.8% 0.17 [0.02, 1.29]
Weiss, 2002 4 12 3 11 1.4% 1.22 [0.35, 4.26]
Wichmann, 2007 1 127 5 129 2.3% 0.20 [0.02, 1.71]
Wu, 2014 1 20 1 20 0.5% 1.00 [0.07, 14.90]
Zhang, 2017 15 157 30 155 13.9% 0.49 [0.28, 0.88]
Study
ω-3
Events Total Events Total Weight M-H, Fixed, 95% CI
Control Risk ratio
M-H, Fixed, 95% CI A B C D E F G
Risk ratio Risk of bias
0.2 0.5
Favors control
1 2 5
Favors ω-3
FA–enriched PN
Figure 2. Infection rates. Forest plot of fixed effects meta-analysis showing individual study means, pooled estimates, and risk of
bias for individual studies (Cochrane tool). CI, confidence interval; FA, fatty acid; PN, parenteral nutrition.
reduction of infection rates (RR 0.60, 95% CI 0.49-0.72;
P < 0.00001) (Figure 2). No subgroup analysis was
performed, as heterogeneity was low (I2: 0%).
The 30-day mortality rate was reported by 20 studies
(1839 patients): 9 studies of ICU patients and 11 for
non-ICU patients (note: in this study, 30-day mortality
was defined as any deaths occurring up to 30 days after
receiving at least 1 dose of study treatment or prior to
hospital discharge, whichever was reported). There was a
nonsignificant 16% reduction in mortality rate (RR 0.84,
95% CI 0.65-1.07; P = 0.15) (Figure 3).
Length of hospital stay was reported by 26 studies (2182
patients), of which 10 were ICU studies and 16 non-ICU
studies, and length of ICU stay was reported by 10 studies
(822 patients). Results showed a reduction in ICU stay of
1.95 days (95% CI 0.42-3.49; P = 0.01) and reduction in
length of hospital stay of 2.14 days (95% CI 1.36-2.93;
P < 0.00001) (Figures 4 and 5, respectively). As data for
both length of stay outcomes were classed as highly het-
erogeneous (I2 > 50%), subgroup analyses were considered.
Although no subgroup analyses were performed for length
of ICU stay (<10 studies were available for each subgroup
analysis), length of hospital stay data were analyzed further.
These subgroup analyses showed significantly greater effect
with no heterogeneity (I2 = 0%) in total PN vs PN groups,
and comparable but less heterogeneous effects in oncolog-
ical studies vs non-oncological studies, and in non-ICU
vs ICU studies. Thus, effects on length of stay were more
consistent in more homogenous groups of patients such as
these.
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(A) Random sequence generation (selection bias)
Risk of bias legend
(G) Other bias
(F) Selective reporting (reporting bias)
(E) Incomplete outcome data (attrition bias)
(D) Blinding of outcome assessment (detection bias)
(C) Blinding of participants and personnel (performance bias)
(B) Allocation concealment (selection bias)
Low risk
High risk
Unclear
Badia-Tahull, 2010 1 13 2 14 1.85% 0.54 [0.06, 5.26] 
Barbosa, 2010 4 13 4 10 4.33% 0.77 [0.25, 2.34]
Berger, 2008 0 12 0 12 0.48% 1.00 [0.02, 46.40]
Chen, 2017 3 24 10 24 9.58% 0.30 [0.09, 0.96]
Chen, 2017 10 40 15 37 14.93% 0.62 [0.32, 1.20]
Friesecke, 2008 18 83 22 82 21.21% 0.81 [0.47, 1.39]
Grau-Carmona, 2015 25 66 21 73 19.11% 1.32 [0.82, 2.12]
Gultekin, 2014 7 16 8 16 7.67% 0.88 [0.42, 1.84]
Klek, 2008 0 51 1 49 0.98% 0.48 [0.02, 14.00]
Klek, 2011 0 42 1 41 1.45% 0.33 [0.01, 7.77]
Llang, 2008 0 20 0 21 0.47% 1.05 [0.02, 50.43]
Makay, 2011 0 14 1 12 1.54% 0.29 [0.01, 6.50]
Mertes, 2006 3 126 4 123 3.88% 0.73 [0.17, 3.20]
Sabater, 2011 4 8 2 8 1.92% 2.00 [0.50, 8.00]
Wang, 2009 0 28 2 28 1.92% 0.25 [0.01, 5.30]
Weiss, 2002 1 12 1 11 1.00% 0.92 [0.06, 12.95] 
Wichmann, 2007 6 127 2 129 1.90% 3.05 [0.63, 14.82]
Zhang, 2017 1 157 5 155 4.82% 0.20 [0.02, 1.67]
Zhu 2013 0 38 0 38 0.48% 1.00 [0.02, 49.11]
Zhu 2012 0 33 0 33 0.48% 1.00 [0.02, 48.92]
Total (95% CI)  923  916 100.0% 0.84 [0.65, 1.07]
Total events 83  101
Heterogeneity: χ2 = 14.93, df = 19 (P = 0.727); I2 = 0%
Test for overall effect: Z = 1.44 (P = 0.15) 
Study Events Total Events Total Weight M-H, Fixed, 95% CI
Control Risk ratio
M-H, Fixed, 95% CI A B C D E F G
Risk ratio Risk of bias
0.1
Favors control
1 10
Figure 3. Thirty-day mortality rates. Forest plot of fixed effects meta-analysis showing individual study means, pooled estimates,
and risk of bias for individual studies (Cochrane tool). Note: to correct for the 0 event studies as per the protocol (to add 0.5
events in both arms), this meta-analysis was performed using STATA software, as it is difficult to use RevMan for this correction.
CI, confidence interval; FA, fatty acid; PN, parenteral nutrition.
Sepsis was reported in 9 studies (1141 patients), of which
2 were ICU studies and 7 non-ICU studies. Compared
with standard lipid emulsions, ω-3 fatty-acid enriched PN
resulted in a significant 56% reduction in the risk of sepsis
(RR 0.44, 95% CI 0.28-0.70; P = 0.0004) (Figure 6). No
meta-analyses were performed on hospital readmissions,
ICU-free days, or ventilation-free days, as only 1 or no
studies reported each of these outcomes.
Trial sequential analysis for all significant clinical out-
comes (infection rate, length of hospital stay, length of ICU
stay, and sepsis) showed adequate power (Figures S1–S4),
and thus these estimates can be considered conclusive.
Nonclinical Outcomes
Significant benefits were found in 10 of the 24 laboratory pa-
rameters analyzed (Table S2). Thesewere significant benefits
in marker liver enzyme levels (AST, ALT, and GGT), higher
levels of the antioxidant α-tocopherol, as well as lower levels
for markers of inflammation such as TNF-α. A significant
benefit was observed in fatty-acid profiles, with increases in
levels of the ω-3 fatty acids, DHA, and EPA. A positive
influence was also observed on LT levels, with a significant
increase in LTB5 levels as well as on the LTB5:LTB4 ratio.
PTT also increased significantly.
Confidence in Cumulative Estimate and
Meta-Bias and Meta-Regression Results
Confidence in cumulative estimates for clinical outcomes
was high for infection and sepsis rates andmoderate for both
length of hospital and ICU stays (Table S3). Confidence in
cumulative estimates for laboratory parameters was either
high or moderate, except TNF-α, which was judged as low.
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Low risk
High risk
Unclear
Barbosa, 2010 12 14.42 13 13 12.65 10 1.8% –1.00 [–12.09, 10.09]
Chen, 2017 13.8 9.9 24 24.4 23.2 24 2.1% –10.60 [–20.69, –0.51]
Wichmann, 2007 4.1 1.6 127 6.3 2.5 129 21.0% –2.20 [–2.71, –1.69]
Weiss, 2002 4.1 1.4 12 9.1 1.2 11 19.5% –5.00 [–6.06, –3.94]
Wang, 2008 21.4 18.78 20 27.5 25.04 20 1.2% –6.10 [–19.82, 7.62]
Wachtler, 1997 0.9 6.1 19 2 19.25 21 2.7% –1.10 [–9.78, 7.58]
Heller, 2004 4.3 1.37 24 4.59 1.97 20 19.7% –0.29 [–1.31, 0.73]
Grau-Carmona, 2015 16.97 16.55 81 18.99 9.53 78 8.3% –2.02 [–6.20, 2.16]
Friesecke, 2008 28 25 83 23 20 82 4.0% 5.00 [–1.90, 11.90]
Berger, 2008 1.76 0.99 12 2.52 1.56 12 19.6% –0.76 [–1.81, 0.29]
Total (95% CI)   415   407 100.0% –1.95 [–3.49, –0.42]
Heterogeneity: τ2 = 2.86, χ2 = 54.27, df = 9 (P < 0.00001); I2 = 83%
Test for overall effect: Z = 2.49 (P = 0.01)
Study Mean SD Total
Control
Mean SD Total Weight IV, Random, 95% CI A B C D E F G
Mean difference
IV, Random, 95% CI
Mean difference Risk of bias
–10 –5
Favors control
0 5 10
(A) Random sequence generation (selection bias)
Risk of bias legend
(G) Other bias
(F) Selective reporting (reporting bias)
(E) Incomplete outcome data (attrition bias)
(D) Blinding of outcome assessment (detection bias)
(C) Blinding of participants and personnel (performance bias)
(B) Allocation concealment (selection bias)
Figure 4. Length of intensive care unit stay. Forest plot of random effects meta-analysis showing individual study means, pooled
estimates, and risk of bias for individual studies (Cochrane tool). CI, confidence interval; FA, fatty acid; IV, inverse variance; PN,
parenteral nutrition; SD, standard deviation.
Low risk
High risk
Unclear
Aliyazicioglu, 2013 7.13 1.73 8 12.48 5.43 10 3.4% –5.35 [–8.92, –1.78]
Chen, 2017 20.3 2.29 40 21 2.68 40 9.0% –0.70 [–1.79, 0.39]
Friesecke, 2008 28 25 83 23 20 82 1.2% 5.00 [–1.90, 11.90]
Grau-Caromona, 2015 32.97 29.09 81 40.7 25.23 78 0.8% –7.73 [–16.18, 0.72]
Grimm, 2006 13.4 2 19 20.4 10 14 1.8% –7.00 [–12.31, –1.69]
Gultekin, 2014 31.6 17.2 16 30.6 17.2 16 0.4% 1.00 [–10.92, 12.92]
Heller, 2004 19.1 47.03 24 18.8 37.57 20 0.1% 0.30 [–24.70, 25.30]
Jiang, 2010 15 5 100 17 8 103 6.9% –2.00 [–3.83, –0.17]
Klek, 2008 12.5 3.3 51 12.9 4.9 49 7.4% –0.40 [–2.04, 1.24]
Klek, 2005 14.4 9.28 29 16.4 9.9 29 2.1% –2.00 [–6.94, 2.94]
Liang, 2008 17.45 4.8 20 19.62 5.59 21 3.9% –2.17 [–5.35, 1.01]
Ma, 2012 12.2 6.2 20 10.4 2.7 20 4.3% 1.80 [–1.16, 4.76]
Makay, 2011 13.1 5.51 14 14 6.04 12 2.4% –0.90 [–5.37, 3.57]
Mertes, 2006 15.7 6.3 99 17.8 13.2 100 4.4% –2.10 [–4.97, 0.77]
Wachtler, 1997 20.1 29.64 19 22.4 49.49 21 0.1% –2.30 [–27.31, 22.71]
Wang, 2008 62.2 32.65 20 70.5 40.7 20 0.1% –8.30 [–31.17, 14.57]
Weiss, 2002 17.8 3 12 23.5 3 11 5.3% –5.70 [–8.15, –3.25]
Wichmann, 2007 17.2 6.7 127 21.9 8.7 129 6.7% –4.70 [–6.60, –2.80)
Wu, 2014 17.45 4.8 20 19.62 5.59 20 3.8% –2.17 [–5.40, 1.06]
Zhang, 2017 10.17 3.15 157 12.56 3.21 155 10.1% –2.39 [–3.10, –1.68]
Zhu, 2012 12 4 29 15 6 28 4.9% –3.00 [–5.66, –0.34]
Zhu, 2013 13.5 3.8 38 15.3 4.3 38 6.9% –1.80 [–3.62, 0.02]
Zhu, 2012 18.7 4 33 20.6 4.6 33 6.2% –1.90 [–3.98, 0.18]
Berger, 2008 9.54 1.84 12 11.08 2.46 12 7.1% –1.54 [–3.28, 0.20]
Barbosa, 2010 22 25.24 13 55 50.6 10 0.1% –33.0 [–67.23, 1.23]
Badia-Tahull, 2010 18.65 13 13 16.1 8.7 14 0.8% 2.55 [–5.86, 10.96]
Total (95% CI)   1097   1085 100.0% –2.14 [–2.93, –1.36]
Heterogeneity: τ2 = 1.46, χ2 = 51.47, df = 25 (P = 0.001); I2 = 51%
Test for overall effect: Z = 5.35 (P < 0.00001)
Study
ω-3
Mean SD Total
Control
Mean SD Total Weight IV, Random, 95% CI A B C D E F G
Mean difference
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(F) Selective reporting (reporting bias)
(E) Incomplete outcome data (attrition bias)
(D) Blinding of outcome assessment (detection bias)
(C) Blinding of participants and personnel (performance bias)
(B) Allocation concealment (selection bias)
Figure 5. Length of hospital stay. Forest plot of random effects meta-analysis showing individual study means, pooled estimates,
and risk of bias for individual studies (Cochrane tool). CI, confidence interval; FA, fatty acid; IV, inverse variance; PN, parenteral
nutrition; SD, standard deviation.
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(A) Random sequence generation (selection bias)
Risk of bias legend
(G) Other bias
(F) Selective reporting (reporting bias)
(E) Incomplete outcome data (attrition bias)
(D) Blinding of outcome assessment (detection bias)
(C) Blinding of participants and personnel (performance bias)
(B) Allocation concealment (selection bias)
Low risk
High risk
Unclear
Badia-Tahull, 2010 1 13 5 14 8.9% 0.22 [0.03, 1.61]
Jiang, 2010 4 100 13 103 23.8% 0.32 [0.11, 0.94]
Klek, 2008 1 51 2 49 3.8% 0.48 [0.04, 5.13]
Total (95% CI)  571  570 100.0% 0.44 [0.28, 0.70]
Total events 24  54
Heterogeneity: χ2 = 3.85, df = 8 (P = 0.87); I2 = 0%
Test for overall effect: Z = 3.52 (P = 0.0004)
Klek, 2011 2 42 2 41 3.8% 0.98 [0.14, 6.61]
Wang, 2012 1 32 4 31 7.5% 0.24 [0.03, 2.05]
Wang, 2008 4 20 9 20 16.7% 0.44 [0.16, 1.21]
Zhang, 2017 3 157 3 155 5.6% 0.99 [0.20, 4.82]
Zhu, 2012 4 29 11 28 20.8 0.35 [0.13, 0.97]
Wichmann, 2007 4 127 5 129 9.2% 0.81 [0.22, 2.96]
Study Events Total Events Total Weight M-H, Fixed, 95% CI
Control Risk ratio
M-H, Fixed, 95% CI A B C D E F G
Risk ratio Risk of bias
0.1 0.2 0.5
Favors control
1 2 5 10
Figure 6. Sepsis. Forest plot of fixed effects meta-analysis showing individual study means, pooled estimates, and risk of bias for
individual studies (Cochrane tool). CI, confidence interval; FA, fatty acid; PN, parenteral nutrition.
The potential formeta-bias (reporting bias) was explored
by funnel plots for clinical outcomes. These appeared sym-
metrical, and there was no evidence of significant bias on
the weighted regression using either Begg’s or Egger’s tests
(Figure S5). Funnel plots were also performed for all other
outcomes, and none showed evidence of bias.
Univariate and multivariate meta-regression were per-
formed for length of hospital stay. Univariate meta-
regression found no potential associations between length
of hospital stay and the exclusiveness of parenteral ad-
ministration (P = 0.1868), reason for PN (P = 0.6406),
nutrition status of malnourished or non-malnourished (P=
0.2281), ICU or non-ICU setting (P = 0.0956), medical vs
surgical ICU setting (P = 0.8161), or patients’ oncological
status (P = 0.7452), infection rate difference between the
treatment and control groups (P = 0.1485), or mean age
(P = 0.3710). However, univariate meta-regression found
a significant association between treatment effect estimate
and the mortality difference between the treatment and
the control group (P = 0.0255). Nevertheless, there were
more deaths in the control group, excluding any hypoth-
esis that saved hospital days could be because of excess
mortality in the fish-oil group. Multivariate regression re-
sults (P = 0.0405) were consistent with these, indicating
a potential association between the mortality difference
and treatment effect estimate on the length of hospital
stay.
Discussion
ω-3 Fatty-acid enriched PN significantly reduces the risk
of infections and length of both ICU and hospital stays
compared with standard PN. Furthermore, ω-3 fatty-acid
enriched PN had potentially beneficial effects on liver
chemistry, antioxidant status, markers of inflammation,
coagulation, and fatty-acid profile.
The validity and robustness of results from our previ-
ous publication that encompassed 23 RCTs10 have been
confirmed and extended by the present study using a
much larger and current dataset and the addition of trial
sequential analysis. Moreover, this update was needed, as
the Cochrane Collaboration recommends that systematic
reviews andmeta-analyses are updated at least every 2 years,
if possible.12 When comparing the results of the previous
meta-analysis10 and this update, there is a great degree of
similarity, but an increased number of patients have resulted
in greater precision (narrower CIs) (Table S4). The current
results also include sepsis, demonstrating a significant (ap-
proximately 56%) reduction in sepsis associated with the use
of PN including fish oils (P = 0.0004). The only clinical
outcome that was not statistically significant was mortality,
as shown previously.
To the best of our knowledge, the current systematic
review and meta-analysis is the largest conducted to date
on this subject. A number of other meta-analyses have
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compared clinical outcomes for PN enriched with ω-3 fatty
acids vs standard PN in surgical patients,66-70 ICU and/or
critically ill patients,71-73 ICU and non-ICU patients,10,74
or patients with gastrointestinal cancer.75 Only 2 of these
11 meta-analyses failed to find 1 or more significant clin-
ical benefits in favor of ω-3 fatty-acid enriched PN,68,72
though both were probably underpowered, as each only
included 6 RCTs, 1 with a total of 306 patients68 and the
other 390 patients.72 To our knowledge, no meta-analyses
have found any significant clinical benefits in favor of
standard PN.
There is considerable confidence in the effect estimates
of the current study as assessed using GRADE and trial
sequential analysis. This is necessary for the result to be
relevant to clinical practice.76 The quality of evidence for
clinical outcomes and all laboratory parameters (except
TNF-α) were rated as high or moderate. Moreover, there
was no evidence of meta-bias (reporting bias) from funnel
plots. Although we have a high level of confidence in
the meta-analysis estimates, especially infection and sepsis
reduction estimates, ideally it would be useful to confirm
these evaluations by performing further large-scale RCTs.
In particular, large, properly designed trials are required to
prove or reject any effect on mortality rates. Finally, we
adhered to best practices, such as prospective registration
of methods and following the PRISMA statement for
reporting systematic reviews and meta-analyses.
In summary, this meta-analysis confirms and extends
previous results in greater numbers of patients and clinical
trials, providing greater precision. It provides clear evidence
that omega-3 fatty-acid enriched PN provides significant
clinical and nonclinical benefits over standard non-ω-3
fatty-acid enriched PN in adult hospitalized patients.
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